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The direct relationship between the aging process and the
incidence and prevalence of both benign prostatic hyper-
plasia (BPH) and prostate cancer (PCa) implies that certain
risk factors associated with the development of both
diseases increase with the aging process. In particular,
both diseases share an overly proliferative phenotype,
suggesting that mechanisms that normally act to suppress
cellular proliferation are disrupted or rendered dysfunc-
tional as a consequence of the aging process. We propose
that one such mechanism involves changes in the prostate
microenvironment, which ‘evolves’ during the aging pro-
cess and disrupts paracrine interactions between epithelial
and associated stromal fibroblasts. We show that stromal
fibroblasts isolated from the prostates of men 63–81 years
of age at the time of surgery express and secrete higher
levels of the CXCL12 chemokine compared with those
isolated from younger men, and stimulate CXCR4-mediated
signaling pathways that induce cellular proliferation. These
studies represent an important first step towards a
mechanistic elucidation of the role of aging in the etiology
of benign and malignant prostatic diseases.





Benign prostatic hyperplasia (BPH), or noncancerous enlargement
of the prostate, is a common condition associated with aging





















higher proliferative and lower apoptotic rates for epithelial cells
from hyperplastic compared with normal prostates, suggesting
that some proportion of increased prostate volume with age is













., 2001). However, the
molecular mechanisms responsible for increased epithelial
cell proliferation in hyperplastic human prostates are not well








 models have suggested that paracrine inter-
actions between glandular epithelial cells and adjacent fibroblastic
stromal cells play an important role in the development of

























., 2002). Although useful for the study
of various aspects of epithelial–stromal interactions, it is unclear
whether rodent-based models accurately recapitulate such
interactions in the human prostate. In order to create a human-
based system for the study of paracrine interactions during










most successful efforts to date have utilized cocultured normal
human prostate-derived fibroblasts and the LNCaP prostate




., 1998). These studies
clearly demonstrated that epithelial–stromal paracrine interac-
tions were required for xenografted LNCaP cells to fully express














 studies described above show that
epithelial–stromal interactions are crucial for the regulation of
epithelial cell growth. However, because the etiologies of BPH
and prostate cancer (PCa) are clearly associated with aging, it is
important to determine whether epithelial–stromal interactions
in the human prostate change over time and how such changes
contribute to the development of hyperplasia and cancer. The
studies reported here are the first to examine the effects of an
aging microenvironment on paracrine interactions and prostatic





 model system for benign prostatic hyperplasia
developed in our laboratory. The epithelial component of this
model, N15C6 cells, was developed from immortalized primary
normal prostate epithelial cells. The stromal component consisted
of stromal fibroblastic cell populations cultured from the prostates
of patients aged 40–52 years (younger) or 63–81 years (older) at
the time of surgery. Experiments accomplished using this model
show that stromal fibroblast cells cultured from the prostates of
older men were less able to suppress epithelial cell proliferation
than those cultured from the prostates of younger men. More-
over, older fibroblasts expressed and secreted higher levels of
the chemokine CXCL12 compared with younger fibroblasts,
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enhanced epithelial cell proliferation. This is the first report to
demonstrate that an aging microenvironment directly contributes
to the disruption of normal human prostatic stromal–epithelial
interactions and that this disruption causes enhanced epithelial




Older fibroblasts are less able to repress epithelial cell 




N15C6 human prostate epithelial cells demonstrated differential
growth in conditioned media acquired from fibroblast cell
populations originating from younger (40–52 years old) com-
pared with older (63–72 years old) patients (Fig. 1). The average
cell number for N15C6 cells grown in defined serum-free HIE





 16 400) cells, was significantly less than that for the same cells









 0.001) (Fig. 1). This suggested that conditioned media from
younger fibroblast cells exerted a growth-suppressive effect
on N15C6 prostate epithelial cells. In contrast, the average cell
number for N15C6 cells grown in the presence of defined serum-





 40 000) cells, was significantly higher than that for
the same cells grown in the presence of defined serum-free HIE




 0.001) and was
close to that obtained using defined serum-free HIE conditioned
media alone (Fig. 1). Conditioned media acquired from the
fibroblasts of two older men, case no. 9303 (72 years old) and
case no. 11084 (81 years old), elicited a proliferative response
from N15C6 cells that actually exceeded the response observed
using defined serum-free HIE media alone (Fig. 1). Taken together,
these results demonstrate that conditioned media from older
prostate fibroblasts were less able to suppress N15C6 prostate
epithelial cell growth, and in two instances actually induced
N15C6 cell growth.
The fibroblasts used in the experiments described above were
grown in culture from histologically verified benign tissues with
one exception, case no. 091-08, which were grown from tissue
containing malignant prostate glands. Interestingly, conditioned
media from these cancer-associated fibroblasts were not growth
suppressive, even though the tissue was acquired from a patient
49 years of age at the time of surgery and therefore defined in
our study as a member of the ‘younger’ patient group.
 
Differential gene expression patterns distinguish older 
fibroblasts from younger prostate fibroblasts
 
The gene expression profiles of four fibroblast cell populations
derived from younger patients, case nos 11033 (40 years old),
10063 (40 years old), 2396 (51 years old) and 1484 (52 years old)
and of two derived from older patients, case nos 1442 (64 years old)
and 8283 (71 years old), was obtained using Affymetrix U133A
GeneChips and compared. These experiments identified 54 unique,
differentially expressed, transcripts, with 41/54 (76%) up-regulated
and 13/54 (24%) down-regulated in older compared with younger
stromal fibroblasts. Nine of the transcripts that were up-regulated
in RNA derived from older compared with younger prostate stromal
fibroblasts encoded secreted proteins. Of these transcripts, the most
highly up-regulated was for the gene encoding the secreted
chemokine CXCL12, also known as SDF-1 (stromal derived factor
1), which was present at 3.4-fold higher levels in RNA prepared from
older compared with younger stromal fibroblasts. Quantitative
RT–PCR using a highly sensitive TaqMan assay measured 36-fold





 0.001), confirming that CXCL12 transcripts were
more abundant in older prostate stromal fibroblasts.
 
CXCL12 is secreted by prostate stromal fibroblasts and 
induces prostate epithelial cell proliferation
 
An ELISA specific for CXCL12 confirmed that older stromal
fibroblasts (populations 1442, 12154, 8283 and 10224) secreted
Fig. 1 Conditioned media from aged prostate 
stromal fibroblasts induce growth of N15C6 
prostate epithelial cells. N15C6 prostate epithelial 
cells were grown for 96 h in 5% HIE, defined 
serum-free media (SF HIE) or SF HIE media grown 
for 48 h in the presence of fibroblast cell 
populations indicated by case number and patient 
age (in parentheses). Fibroblast population 091-08 
was derived from cancer-associated stroma; the 
rest were derived from histologically benign 
tissues. Average cell growth in media from younger 
patients (aged 40–52; gray bars) is shown by solid 
line; average growth in media from older patients 
(aged 63–81; black bars) is shown by dashed line. 
Epithelial cell growth was significantly facilitated by 
media from older fibroblasts but inhibited by media 
from younger fibroblasts (P = 0.002).
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) compared with younger











). The same assay did not detect CXCL12 in
culture media from N15C6 cells and detected very low levels of















). These data demonstrated that older prostate
fibroblasts secreted higher levels of CXCL12 than younger
prostate fibroblasts or epithelial cells.
We next examined whether the addition of CXCL12 to defined
serum-free media in the concentration range secreted by older
prostate fibroblasts induced N15C6 or LNCaP prostate epithelial









 for LNCaP cells, was growth
stimulatory and facilitated growth significantly above levels





the proliferative effect of low levels of CXCL12 was modest,
the addition of higher concentrations of CXCL12 in both cases
was clearly growth inhibitory. Together with the conditioned
media experiments reported above, these results show that
CXCL12 is secreted by human prostate stromal fibroblasts and
directly stimulates human prostate epithelial cell proliferation at
very low, picomolar concentrations.
 
CXCL12 stimulates phosphorylation of ERK 1/2 
and NF-kappaB
 
Of the three major downstream signaling pathways stimulated
by CXCR4/CXCL12 binding – PI3K/FAK, Ras/ERK and PI3K/NF-
kappaB – both the Ras-mediated ERK pathway and the PI3K-
mediated NF-kappaB pathway are associated with cellular
proliferation. We therefore tested whether CXCL12, which was
observed to induce N15C6 and LNCaP cellular proliferation, also
induced ERK and/or NF-kappaB activation. As seen in Fig. 3,













induced rapid, transient ERK phosphorylation and activation.
ERK phosphorylation was maximal after 10 min of exposure to








CXCL12. Phosphorylation of the p65 subunit of NK-kappaB was














CXCR4 levels were not detectably altered in cells exposed to
CXCL12 over the same time period (Fig. 3). These data show
that even the very low levels of CXCL12 secreted by older
prostate fibroblasts and associated with N15C6 and LNCaP
cellular proliferation are sufficient for phosphorylation and
activation of ERK 1/2 and NF-kappaB.
 
CXCL12 and CXCR4 proteins are expressed by human 
prostate tissues
 
Immunohistochemical analysis of a tissue microarray (TMA)
was used to assess CXCL12 and CXCR4 protein expression in
human prostate tissues (Fig. 4). Benign glands (24 tissue cores),
epithelial BPH (BPH-E, 65 cores), and malignant glands (77 cores)
demonstrated both CXCL12 and CXCR4 protein expression.
Benign glands demonstrated the highest levels of expression for
both proteins (Fig. 5). Malignant glands and BPH-E demon-
strated equivalent CXCR4 expression, and CXCL12 levels were
Fig. 2 Low [CXCL12] induces the proliferation of N15C6 and LNCaP prostate 
epithelial cells. N15C6 or LNCaP prostate epithelial cells were grown for 72 h 
in complete media (5% HIE for N15C6, 10% RPMI for LNCaP), defined 
serum-free HIE (SF) or SF supplemented to the indicated concentration of 
CXCL12. N15C6 cellular proliferation was induced above SF levels at 1–3 pM 
CXCL12 but was suppressed at 1000 pM CXCL12, whereas LNCaP 
proliferation was induced at 50 pM CXCL12 (P < 0.001).
Fig. 3 Low [CXCL12] induces ERK and NF-kappaB phosphorylation. N15C6 
cells were grown in 5% HIE media supplemented to 1, 10, or 1000 pM 
CXCL12 for 0, 5, 10, 15 or 20 min, then harvested, lysed, and examined by 
Western blot analysis. The treatment did not affect total levels of the ERK or 
NF-kappaB (p65) proteins, but did rapidly and transiently induce ERK 
phosphorylation (ppERK) and NF-kappaB (pp65). Actin is shown as a loading 
control (bottom panel). CXCR4 and actin expression are also shown for 
N15C6 cells in serum-free media (lane 1), LNCaP cells (lane 2) and two primary 
cultures of explanted prostate epithelial tissues (lanes 3 and 4) as controls.
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approximately half that of CXCR4 levels in the same tissues (Fig. 5).
The expression pattern for CXCR4 was cytoplasmic and/or mem-
braneous (Fig. 4A,B,D) with the exception of 14/65 (21%)
samples of BPH-E, which demonstrated strong nuclear staining
(Fig. 4C). The expression pattern for CXCL12 appeared to be
exclusively membrane-bound, and likely reflected detection of




Several studies have shown that epithelial–stromal interactions
are crucial for the regulation of epithelial cell growth. We have
hypothesized that epithelial–stromal interactions in the human
prostate change over time and that these changes may
contribute to the development of hyperplasia and cancer. To
test this hypothesis, we have examined the effects of an aging
microenvironment on paracrine interactions and prostatic





for benign prostatic hyperplasia developed in our laboratory.
The results of these experiments show that the prostate stroma
overall exerts a repressive effect on prostate epithelial cell growth.
This finding is consistent with the observation that paracrine
interactions between human prostate epithelial cells and rat
urogenital sinus mesenchyme act homeostatically to maintain








., 1998). Even so, the results of our
studies also show that growth of the N15C6 human prostate
epithelial cells in media conditioned by older (patients aged 63–
81 years) stromal fibroblasts was clearly enhanced compared
with growth in media conditioned by younger (patients aged
40–52 years) fibroblasts. In two instances (cases nos 9303 and
11084), N15C6 epithelial cell growth in media conditioned by
older prostate fibroblasts actually exceeded levels obtained in
complete media (5% HIE). This implies that suppression of
Fig. 4 Benign, hyperplastic and malignant human 
prostate glands express CXCR4 and CXCL12. 
Representative portions of identical tissue 
microarrays are shown of human benign prostate 
tissues (A, E), benign prostatic hyperplasia, 
epithelial tissues (B, C, F, G), and malignant 
prostate tissues (D, H) after incubation with primary 
antibodies against CXCR4 (1 : 100) (A–D) or 
CXCL12 (1 : 100) (E–H) and visualization using 
immunoperoxidase staining.
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epithelial cell proliferation is less efficient in the aging prostate,
and that this reduction in efficiency can be directly attributable
to paracrine interactions with aging stromal fibroblasts. Inter-
estingly, conditioned media from the single cancer-associated
fibroblast population were not growth suppressive, even though
the tissue was acquired from a patient 49 years of age at the time
of surgery and therefore defined in our study as a member of
the ‘younger’ patient group. This observation is consistent with
other studies suggesting that cancer-associated fibroblasts may






Our studies also showed that older prostate stromal fibroblasts
transcribe the CXCL12 gene and secrete higher levels of the
CXCL12 protein compared with younger stromal fibroblasts.
Moreover, ‘add back’ assays demonstrated that low, picomolar
concentrations of CXCL12 directly stimulate human prostate
epithelial cell proliferation, and that this effect is likely mediated
through phosphorylation and activation of ERK 1/2 and NF-kappaB.
The chemokine CXCL12 and its receptor, CXCR4, are known to





., 1994; Moser & Loetscher, 2001). These
molecules have also been recently implicated in cancer cell migra-
tion and invasion. Cultured prostate cancer cells have been shown
to migrate and invade through extracellular matrix and to migrate
across bone marrow endothelial cell monolayers in response to
CXCL12, activities that can be blocked by pretreatment with













., 2004). Cultured breast can-
cer cells demonstrate enhanced chemotaxis, chemoinvasion and
adhesive properties in response to CXCL12, and cells ‘knocked
down’ for CXCR4 transcripts demonstrate significantly reduced

















., 2005). Taken together,
these studies indicate a role for CXCL12/CXCR4 interactions in
breast and prostate cancer cell migration and invasion. Several
of these reports also noted that breast and prostate cancer cells
did not proliferate in response to nanomolar levels of CXCL12,


















., 2004). We now report that CXCL12 levels








 for LNCaP prostate
epithelial cells stimulate cellular proliferation and that higher levels
are clearly growth inhibitory. Together with the studies cited above,
this finding suggests that CXCL12 exerts a concentration-
dependent dual effect on prostate epithelial cell biology, i.e.
lower, picomolar levels stimulate proliferation whereas higher,
nanomolar levels repress proliferation but induce motility and
invasiveness. These results are consistent with roles for CXCL12/
CXCR4 interactions in the etiologies of both benign proliferative
disease (BPH) and malignant disease (PCa) in the prostate.
Moreover, our observations that low, picomolar levels of CXCL12
equivalent to those secreted by older prostate fibroblasts are
associated with prostate epithelial cell proliferation, as well as
with activation of ERK 1/2 and NF-kappaB, mechanistically links
CXCL12/CXCR4 binding, epithelial/stromal fibroblast paracrine
interactions, and epithelial cellular proliferation in the context
of an aging microenvironment.
Although the proliferative effects observed for prostate
epithelial cells after growth in picomolar levels of CXCL12 were
modest, our studies identified several transcripts corresponding to
growth-stimulatory secreted proteins. Therefore, the incremental
induction of cellular proliferation by CXCL12 likely reflects the
effects of just one of several growth-stimulatory factors secreted
by aging prostate fibroblasts. As these factors are validated and




 system, it is likely that, together, they will
recapitulate the significant growth-stimulatory effects observed
after exposure of prostate epithelial cells to media conditioned
by aging fibroblasts.
The immunohistochemical analyses reported here demon-
strate CXCR4 protein expression and less abundant CXCL12
expression in epithelial cells associated with benign glands, BPH
nodules characterized by epithelial hyperplasia (BPH-E) and
malignant glands, but not in BPH nodules characterized by
stromal hyperplasia (BPH-S). CXCR4 demonstrated cytoplasmic
and membraneous staining whereas CXCL12 appeared to be
exclusively membrane-bound, and likely reflected detection of
the protein bound to the CXCR4 receptor. The lack of expression
of both CXCR4 and CXCL12 in BPH-S tissues indicates that CXCR4
protein is not expressed in these tissues and that CXCL12 is
virtually undetectable in the absence of its receptor. Interestingly,
glandular epithelial cells within BPH-E tissue sections demon-
strated the most diverse patterns of CXCR4 expression, with
14/65 (21%) of samples exhibiting exclusively nuclear staining,
20/65 (31%) exhibiting both cytoplasmic and nuclear staining, and
25/65 (38%) exhibiting exclusively cytoplasmic staining. A recent
retrospective study of tissues resected from stage I non-small-cell
lung cancer patients described strong nuclear staining in 29.8%
of tumors, and showed that nuclear localization for CXCR4 was





Fig. 5 Quantitation of tissue microarray immunohistochemical analysis. 
The percent expression of CXCR4 and CXCL12 in Benign, BPH-E, BPH-S 
and Tumor prostate tissues is shown. Gray bars, staining score 0–100; 
black bars, score > 100.
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2004). It is known that CXCR4 undergoes endocytosis mediated
by clathrin-coated pits, that this mechanism permits recycling
of CXCR4 between the cell membrane and endosomal com-
partments in hematopoetic progenitor cells and T-cells, and that
this process is constitutive in some cells but can be accelerated









the nuclear localization of CXCR4 observed here and by others
is due to a disruption or evasion of normal CXCR4 recycling,
or to an independent and alternate mechanism, remains to be
elucidated.
In summary, these studies show that stromal fibroblasts from
the prostates of older men are less able to suppress epithelial
cell proliferation than those from younger men, that this effect
is at least partially mediated by oversecretion of the CXCL12
chemokine, and that low, picomolar levels of CXCL12 equivalent
to those secreted by older prostate stromal fibroblasts initiates
a signaling cascade that triggers epithelial cell proliferation. This
work represents an important first step towards a mechanistic
elucidation of the role of aging in the etiology of benign and
malignant prostatic diseases. Future studies focusing on how
the balance of growth factors and growth repressors secreted
by stromal fibroblasts becomes altered within the context of an
aging microenvironment will further elucidate how the aging
process directly contributes to the development of hyperplasia




Establishment of cell cultures
 
All tissue acquisition and processing protocols conformed
to those reviewed and approved by the University of Michigan
Institutional Review Board. Normal prostate tissue samples were
obtained aseptically from patients undergoing radical prostate-
ctomy or cystoprostatectomy after cancer diagnosis. Tissue was
taken exclusively from the transitional zone of the prostate
surrounding the urethra to facilitate the isolation of fibroblasts
associated with benign prostatic hyperplasia (BPH). A small slice




25%) was fixed in 10% formalin for immuno-
histochemical examination. The remaining tissue was minced into











C with gentle shaking, spun down, resuspended and
plated in 5% HIE media [Ham’s F12 (Mediatech Inc., Herndon, VA,
USA) with 5% FBS (Invitrogen Life Technologies Inc., Carlsbad,



























cortisone (Sigma Chemical Co., St. Louis, MO, USA). Subcultured
fibroblast cell populations were assessed by immunohistochemistry
using monoclonal antibodies to vimentin or alpha-actin (Sigma-
Aldrich, St. Louis, MO, USA) to distinguish stromal fibroblastic
cells from smooth muscle cells, respectively. The fibroblast cell
populations used in these studies were stained uniformly for
vimentin but not alpha-actin and were maintained in 5% HIE.
The N15C6 cell line was developed as described previously
(Macoska 
 
et al., 2004; Begley et al., 2005). For conditioned media
experiments, N15C6 cells were grown either in defined
serum-free HIE media supplemented to 5 mM ethanolamine
(Sigma-Aldrich), 10 mM HEPES (Sigma-Aldrich), 5 µg µL−1 trans-
ferrin (Sigma-Aldrich), 10 µM 3,3′,5-triiodo-L-thyronine (Sigma-
Aldrich), 50 µM sodium selenite (Sigma-Aldrich), 0.1% BSA (JRH
Biosciences Lenexa, KS, USA), 0.05 mg mL−1 gentamycin (Gibco,
Carlsbad, CA, USA), and 0.5 µg mL−1 fungizone (Cambrex Bio-
science, Walkersville, MD, USA), or in defined serum-free HIE
conditioned media produced through the incubation of fibro-
blast cell populations in supplemented serum-free HIE media
over a 48-h period. Conditioned media were harvested from
all fibroblast cell populations at passages 1–3 with the exception
of no. 2396 (passage 4), no. 3294 and no. 10063 (passage 5),
and no. 11033 and no. 3382 (passage 11).
Proliferation assays
Cellular proliferation was assessed after plating cells at 50 000
cell/well in triplicate in six-well plates and counting cells after
24 and 96 h of incubation in complete media, serum-free media
or serum-free prostate stromal fibroblast conditioned media, as
described previously (Macoska et al., 2004). Averages and standard
deviations of cell number were calculated for each time point
under each media condition. To assess the effects of exogenous
CXCL12 on cellular proliferation, recombinant human SDF1
alpha/CXCL12 (R & D Systems, 350-NS) was added at the
desired concentration in 1 mL SF HIE (or 1 mL SF HIE alone for
control) to each well. The cells were counted at 24 and 96 h
growth and re-fed at 48 and 72 h growth. Cell counts were
normalized to 50 000 cells at 24 h to account for any plating
discrepancies.
Affymetrix U133A GeneChip data acquisition
RNA was purified from trypsinized cultured cells by homogeniza-
tion in Trizol (Invitrogen, Carlsbad, CA, USA) and additional
processing using the RNeasy (QIAGEN, Valencia, CA, USA) cleanup
procedure. Ten micrograms of RNA obtained from tissues or cell
line was used to obtain labeled cRNA following the Affymetrix
standard protocol. Expression intensity values for each gene
were estimated using a method called Robust Multi-array
Average (RMA) using tools available through Bioconductor
(www.bioconductor.org). GeneChip gene expression values
were normalized using a quantile normalization procedure.
Quantitative real-time PCR
All quantitative real-time assays were conducted with an Applied
Biosystems 7900HT instrument and reagents. One microgram
of RNA was reverse transcribed by use of Superscript III reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). The resulting cDNA
was diluted 1 : 100. Real-time PCR was performed by use of
Assays on Demand (Applied BioSystems, Foster City, CA, USA)
according to the manufacturer’s instructions, except that Real
Time Ready with Rox passive dye (QBioGene, Carlsbad, CA, USA)
CXCL12 enhance proliferation in the aging prostate, L. Begley et al. 297
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was used in place of TaqMan Universal PCR Master Mix. Reactions
were performed in triplicate, including no-template controls and
an endogenous control probe to assess template concentration
(ribosomal protein, large, PO). Cycle numbers to threshold
were calculated by subtracting averaged control from averaged
experimental values, and Fold Gene Expression was calculated by
raising these values to the log 2. FAM conjugated, gene-specific
assays were Hs00171022_m1 for CXCL12, and Hs99999902_m1
for the control, RPLPO.
ELISA assays
Fibroblasts were grown in 0.01% BSA defined HIE for 3 days.
Fibroblast-conditioned media were collected, serially concentrated
using Centriplus Centrifugal Filters (Millipore, Billerica, MA, USA)
with a 3 kDa molecular weight cutoff, and assessed using the
CXCL12/SDF1-alpha ELISA system (R & D Systems). All reactions
were performed in duplicate and the resulting values averaged.
Western blot analysis
Cells were lysed, proteins resolved by electrophoresis and electro-
blotting was carried out as described previously (Chaib et al.,
2001). Proteins were detected using antibodies against phospho-
ERK1/2 (Cell Signaling no. 9101), total ERK1/2 (Cell Signaling,
no. 9102), CXCR4 (Abcam no. ab2074), phospho- p65 (Rockland
no. 100-401-264), total p65 (Rockland no. 100-4165), or beta-actin
(Santa Cruz no. sc-1615), in conjunction with an ECL detection
system.
Construction of tissue microarray (TMA) and 
immunohistochemistry
A TMA was constructed from 31 radical prostatectomy specimens
to represent benign prostate tissues [number of cores (N ) = 24];
benign prostatic hyperplasia epithelial tissues (BPH-E) (N = 65);
benign prostatic hyperplasia stromal tissue (BPH-S) (N = 102) and
prostate cancer (N = 77). Antigen retrieval was performed in
citrate buffer (10 mM, pH 6.0) using a microwave pressure
cooker. The CXCR4 antibody (Abcam, ab2074) was used at 1 : 50
and CXCL12 (R & D Systems, MAB350) at 1 : 100. Digital images
were acquired with the BLISS Imaging System (Bacus Laboratory,
Lombard, IL, USA). Immunostaining intensity was recorded as
absent (1), weak (2), moderate (3), or strong (4) and as the
percentage of cells staining on a scale of 1–100%. The product
of each (intensity × percentage) was used to calculate a staining
score for each tissue. Scoring was performed in a blinded fashion
using the Profiler Web-based telepathology system (http://
pvdb.path.med.umich.edu/htma/profiler/index.jsp).
Statistical analysis
GeneChip expression values were analyzed using a t-statistic
test and by calculation of fold change between data sets. Genes
that exhibited both a large t-statistic (> 10.0) and a large fold
change (> 2.0) were considered to be differentially expressed.
All other data were assessed by t-test or analysis of variance
with P < 0.05 considered statistically significant.
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